CLINICAL STUDIES ON CEFOTIAM HEXETIL
スポンサーリンク
概要
- 論文の詳細を見る
Cefotiam hexetil (CTM-HE), a new orally-absorbed pro-drug of cefotiam, was evaluated clinically in 8 patients (aged 23-67 years, mean 44.8) with respiratory tract infections. The daily dose of CTM-HE was 600 mg in three divided oral doses and the duration of treatment ranged from 4 to 10 days, The results were as follows:<BR>1. The clinical effect of CTM-HE on respiratory tract infections was good in all 8 cases. The efficacy rate was 100%.<BR>2. No side effect was noted.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.